Online inquiry

IVTScrip™ mRNA-Anti-ITGA2, GBR500(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ7437MR)

This product GTTS-WQ7437MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets ITGA2 gene. The antibody can be applied in Multiple sclerosis (MS) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_002203.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3673
UniProt ID P17301
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ITGA2, GBR500(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ7437MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ15962MR IVTScrip™ mRNA-Anti-NGF, ZTS-00508841(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA ZTS-00508841
GTTS-WQ15190MR IVTScrip™ mRNA-Anti-TNF, TA-650(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA TA-650
GTTS-WQ10411MR IVTScrip™ mRNA-Anti-IL17A, LY2439821(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA LY2439821
GTTS-WQ13799MR IVTScrip™ mRNA-Anti-S, REGN-10933(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA REGN-10933
GTTS-WQ11783MR IVTScrip™ mRNA-Anti-IL23A, MK-3222(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MK-3222
GTTS-WQ5398MR IVTScrip™ mRNA-Anti-CD2, CD58-Fc(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA CD58-Fc
GTTS-WQ8635MR IVTScrip™ mRNA-Anti-AXL, HuMax-AXL-ADC(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA HuMax-AXL-ADC
GTTS-WQ9256MR IVTScrip™ mRNA-Anti-CEACAM5, IMMU-130(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA IMMU-130
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW